An Ipamorelin dosage number leaves a lot unsaid.

In the Beck bowel-surgery trial, participants in the Ipamorelin group received 0.03 mg/kg by intravenous infusion twice daily for up to seven days. That was a hospital experiment after bowel surgery, not a personal-use schedule.

Intravenous means into a vein. The main measure, time to the first tolerated meal, didn’t show a statistically significant difference from placebo. I keep that result in the same view as the dose; otherwise the most practical-looking detail loses the reason it was tested.

The healthy-volunteer study also used infusions into a vein. It measured blood levels and growth-hormone release, rather than establishing a treatment schedule for sleep or exercise recovery.

Subcutaneous means under the skin. It isn’t another name for an infusion into a vein. The FDA review didn’t find human data on blood levels or hormone response after the proposed injection under the skin.

That leaves a gap, not a conversion exercise. I don’t turn an infusion result into an injection interval. Evidence about Ipamorelin alone also can’t supply a schedule for a blend with another active ingredient.

If you’re reading a dosing claim, the study name and route help show what it rests on. A number without them can sound more settled than the evidence behind it.

There’s no FDA-approved Ipamorelin medicine or label. On FDA’s page current as of April 22, 2026, Ipamorelin acetate is nominated but withdrawn for 503A and in Category 2 for 503B outsourcing facilities. Those are separate compounding frameworks. I don’t read a withdrawn nomination as approval or permission to compound.

Compounded medicines aren’t FDA-approved. A clinical consultation and the rules for an ingredient are separate parts of the decision. Neither disappears because someone has found a dosing number.